ZYX and Alzheimer disease: In a quantitative mass-spectrometry analysis, Zhong et al. proposed complement component 7 (C7) and zyxin (ZYX) as EV biomarkers that showed expression changes from normal to MCI to AD in NDEs, suggesting they could serve as potential preclinical indicators of impending cognitive decline [72].